Stockscreener 앱 받기
42.86
2.12%
0.89
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
What technical signals suggest for Crinetics Pharmaceuticals Inc. stockTake Profit & Risk Controlled Stock Pick Alerts - newser.com
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Can Crinetics Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe haven assetPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockGlobal Markets & High Return Stock Watch Alerts - newser.com
Price-Driven Insight from (CRNX) for Rule-Based Strategy - news.stocktradersdaily.com
Crinetics begins Phase 3 trial of oral therapy for carcinoid syndrome - Investing.com Nigeria
Crinetics Pharmaceuticals Begins Phase 3 Trial of Paltusotine in Carcinoid Syndrome - MarketScreener
Crinetics (CRNX) Begins Phase 3 Trial for Paltusotine Treatment - GuruFocus
Crinetics announces first patient randomized in pivotal phase 3 CAREFNDR trial evaluating paltusotine in carcinoid syndrome - MarketScreener
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - The Manila Times
Crinetics Pharmaceuticals Advances Phase 3 CAREFNDR Trial for Paltusotine in Treating Carcinoid Syndrome - Quiver Quantitative
Crinetics (Nasdaq: CRNX) Starts Phase 3 CAREFNDR Trial for 141 Carcinoid Patients - Stock Titan
Using data tools to time your Crinetics Pharmaceuticals Inc. exit2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.Entry Point & High Accuracy Swing Trade Signals - newser.com
Why Crinetics Pharmaceuticals Inc. (6Z4) stock attracts HNW investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock cheap by valuation metricsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe buy before earningsQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - newser.com
Is Crinetics Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Closing Moves & Daily Momentum Trading Reports - newser.com
Crinetics Pharmaceuticals Inc.’s volatility index tracking explained2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Can Crinetics Pharmaceuticals Inc. rally from current levels2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
What institutional flow reveals about Crinetics Pharmaceuticals Inc. - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock supported by free cash flowMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
Quantitative breakdown of Crinetics Pharmaceuticals Inc. recent moveJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
Automated trading signals detected on Crinetics Pharmaceuticals Inc.Long Setup & AI Enhanced Market Trend Forecasts - newser.com
Will Crinetics Pharmaceuticals Inc. stock deliver better than expected guidance2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Chart based analysis of Crinetics Pharmaceuticals Inc. trendsMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Crinetics Pharmaceuticals Inc.2025 Year in Review & Free Expert Verified Stock Movement Alerts - newser.com
Backtesting results for Crinetics Pharmaceuticals Inc. trading strategiesStop Loss & Long-Term Safe Investment Ideas - newser.com
1.38%
1.42%
자본화:
|
볼륨(24시간):